Literature DB >> 35349007

Possible Curative Effects of Boric Acid and Bacillus clausii Treatments on TNBS-Induced Ulcerative Colitis in Rats.

Mete Özkoç1, Betül Can2, Hakan Şentürk3, Dilek Burukoğlu Dönmez4, Güngör Kanbak2.   

Abstract

Crohn's disease (CD) and ulcerative colitis (UC) are two chronic relapsing inflammatory bowel diseases (IBD). Although there are several treatment options available to improve the symptoms of IBD patients, there is no effective treatment that provides a definitive solution. In the present study, we aim to investigate the antioxidative/anti-inflammatory effects of oral administration of boric acid and Bacillus clausii in a rat trinitrobenzenesulfonic acid (TNBS)-induced colitis model. The effects of boric acid and B. clausii were examined in serum and colon tissues with the help of some biochemical and histological analyses. Elevated inflammation and oxidative damage were found in the blood and colon tissue samples in the TNBS-induced group according to the complete blood count (CBC), tumor necrosis factor (TNF) alpha, interleukin-35 (IL-35), malondialdehyde (MDA), glutathione peroxidase (GPx), myeloperoxidase (MPO), nitric oxide (NO), and histological findings. Particularly, the highest IL-35 level (70.09 ± 12.62 ng/mL) in the combined treatment group, highest catalase activity (5322 ± 668.1 U/mg protein) in the TNBS-induced group, and lower relative expression of inducible nitric oxide synthase in the TNBS-induced group than the control group were striking findings. According to our results, it can be concluded that boric acid showed more curative effects, even if B. clausii probiotics was partially ameliorative.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bacillus clausii; Boric acid; IL-35; Inflammatory bowel diseases; Probiotics; Ulcerative colitis

Year:  2022        PMID: 35349007     DOI: 10.1007/s12011-022-03215-5

Source DB:  PubMed          Journal:  Biol Trace Elem Res        ISSN: 0163-4984            Impact factor:   3.738


  48 in total

1.  Replenishment of glutathione levels improves mucosal function in experimental acute colitis.

Authors:  E Ardite; M Sans; J Panés; F J Romero; J M Piqué; J C Fernández-Checa
Journal:  Lab Invest       Date:  2000-05       Impact factor: 5.662

Review 2.  Nitric oxide in inflammatory bowel disease.

Authors:  Raymond K Cross; Keith T Wilson
Journal:  Inflamm Bowel Dis       Date:  2003-05       Impact factor: 5.325

Review 3.  Nitric oxide synthases: roles, tolls, and controls.

Authors:  C Nathan; Q W Xie
Journal:  Cell       Date:  1994-09-23       Impact factor: 41.582

Review 4.  Nitric oxide synthases in mammals.

Authors:  R G Knowles; S Moncada
Journal:  Biochem J       Date:  1994-03-01       Impact factor: 3.857

Review 5.  The basics about nitric oxide.

Authors:  Richard Bruckdorfer
Journal:  Mol Aspects Med       Date:  2005-01-24

6.  Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease.

Authors:  Catalina Abad; Carmen Martinez; Maria G Juarranz; Alicia Arranz; Javier Leceta; Mario Delgado; Rosa P Gomariz
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

Review 7.  Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause?

Authors:  Ali Rezaie; Robyn D Parker; Mohammad Abdollahi
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

Review 8.  Crohn's disease.

Authors:  Joana Torres; Saurabh Mehandru; Jean-Frédéric Colombel; Laurent Peyrin-Biroulet
Journal:  Lancet       Date:  2016-12-01       Impact factor: 79.321

Review 9.  Inflammatory bowel disease Part 1: ulcerative colitis--pathophysiology and conventional and alternative treatment options.

Authors:  Kathleen A Head; Julie S Jurenka
Journal:  Altern Med Rev       Date:  2003-08

10.  Myeloperoxidase-derived oxidation: mechanisms of biological damage and its prevention.

Authors:  Michael J Davies
Journal:  J Clin Biochem Nutr       Date:  2010-12-28       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.